Brief: Immunocore Announces FDA Approval Of KIMMTRAK® (tebentafusp-tebn) For The Treatment Of Unresectable Or Metastatic Uveal Melanoma

Immunocore Holdings

26/01/2022 13:02

Jan 26 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE ANNOUNCES FDA APPROVAL OF KIMMTRAK®
(TEBENTAFUSP-TEBN) FOR THE TREATMENT OF UNRESECTABLE OR
METASTATIC UVEAL MELANOMA

Source text for Eikon:  ID:nGNX1r2vjv 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))